CD5 and diffuse large B-cell lymphoma: Although it was discovered in early studies that CD5+ DLBCL cases were mainly ABC subtype (22), implying that CD5+ DLBCLs may respond to therapy targeted on ABC DLBCL (23), the pathological and genetic characteristics of CD5+ DLBCL are not yet fully understood, which has hampered the investigation into targeted therapies.